Document is current
Any future updates will be listed below
-
Authors
Makovec, Allison
Boytim, Ella
Gustafson, Ava
Ludwig, Megan
Wang, Liangjun
Ali, Atef
Ishani, Khalid
Luo, Christine
Bergom, Hannah E.
John, Emily
Tape, Sydney
Kellen, Samuel
Deacon, Aiden
Dewji, Fatemah Iman
Richter, Camden
Cookle, Lauren
Moline, David
Rennhack, Jonathan P.
Drake, Justin M.
Antonarakis, Emmanuel S.
Largaespada, David A.
Ostrander, Julie H.
Hwang, Justin
-
Funding
Funding for this research was provided by:
Undergraduate Research Opportunities Program - University of Minnesota
Research and Travel Fund Award - University of Minnesota
NIH NCI (R01CA269801)
American Cancer Society Research Professorship
NCI/ NIH (5R01CA236948)
Hope for Change Funds - University of Minnesota
Randy Shaver Foundation Community Funds
NCI/NIH (R37 1R37CA288972-01)
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 11 July 2025
First Online: 6 August 2025
Competing interests
: A.M. consults for EMRGNSE LLC, but the business of this company is unrelated to the contents of this manuscript. E.B. consults for Tempus and EMRGNSE LLC, but the business of these companies is unrelated to the contents of this manuscript. H.E.B. is a co-founder of EMRGNSE LLC, but the business of this company is unrelated to the contents of this manuscript. D.M. consults for Tempus, but the business of these companies is unrelated to the contents of this manuscript. J.H. consults for Tempus and is a co-founder of EMRGNSE LLC, but the business of these companies is unrelated to the contents of this manuscript. J.M.D. has no conflicts relevant to this work. However, he serves as a consultant and Chief Scientific Officer of Astrin Biosciences. The interest related to J.M.D. has been reviewed and managed by the University of Minnesota in accordance with its Conflict-of-Interest policies. D.A.L. is the co-founder and co-owner of NeoClone Biotechnologies, Inc., Discovery Genomics, Inc. (recently acquired by Immusoft, Inc.), B-MoGen Biotechnologies, Inc. (recently acquired by Bio-Techne Corporation), and Luminary Therapeutics, Inc. D.A.L. holds equity in, serves as a Senior Scientific Advisor for and Board of Director member for Recombinetics, a genome editing company. The business of all these companies is unrelated to the contents of this manuscript. D.A.L. consults for Styx Therapeutics, Inc. and Genentech, Inc., which is funding some of his research. E.S.A. reports grants and personal fees from Janssen, Sanofi, Bayer, Bristol Myers Squibb, Curium, Merck, Pfizer, AstraZeneca, Clovis, Constellation; personal fees from Astellas, Amgen, Blue Earth, Exact Sciences, Invitae, Eli Lilly, and Foundation Medicine; grants from Novartis, Celgene, and grants from Orion outside the submitted work; and has a patent for an AR-V7 biomarker technology that has been licensed to Qiagen.
